Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Protagenic Therapeutics ( (PTIX) ) has shared an announcement.
On February 17, 2026, Protagenic Therapeutics, Inc. entered into a settlement agreement with Alterola Biotech Inc., EMC2 Capital LLC and the former stockholders of Phytanix Bio to resolve Delaware litigation arising from their prior share exchange deal. The settlement provides for dismissal of the case with prejudice and clears claims related to Protagenic’s 2025 acquisition of Phytanix Bio.
On the same date, the parties executed and closed an Unwind, Termination and Share Exchange Agreement that terminated the May 15, 2025 share exchange and fully reversed the Phytanix transaction. Protagenic returned 100% of Phytanix Bio’s shares to the former stockholders, received back for cancellation all PTIX shares previously issued as consideration, paid Phytanix Bio $300,000 plus a contingent $10,000, and put in place mutual releases, resignations and indemnities reallocating post‑closing liabilities.
The unwind means Protagenic no longer owns Phytanix Bio, which retains its pre‑merger assets and liabilities as of the unwind date. For shareholders and counterparties, the agreements effectively restore the pre‑deal ownership structure while eliminating ongoing litigation risk and clarifying responsibility for potential third‑party claims tied to the short‑lived combination.
Spark’s Take on PTIX Stock
According to Spark, TipRanks’ AI Analyst, PTIX is a Underperform.
Protagenic Therapeutics faces significant financial difficulties, with no revenue and persistent losses. Technical indicators suggest weak market momentum, and the company’s valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score, reflecting substantial risks and challenges.
To see Spark’s full report on PTIX stock, click here.
More about Protagenic Therapeutics
Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic products, operating through corporate structures that include share exchange transactions and strategic acquisitions. Its activities involve complex capital markets dealings, including issuing and canceling common and preferred stock tied to mergers and subsequent unwinding agreements.
Average Trading Volume: 95,127
Technical Sentiment Signal: Sell
Current Market Cap: $809.7K
Find detailed analytics on PTIX stock on TipRanks’ Stock Analysis page.